Publication: Development of a multiple-unit system: Tablets containing amlodipine besylate which have different release kinetics
| dc.contributor.author | TEKDEMİR, OZAN | |
| dc.contributor.author | UĞURLU, TİMUÇİN | |
| dc.contributor.authors | Tekdemir, Ozan; Tilki, Gizem; Ugurlu, Timucin | |
| dc.date.accessioned | 2022-03-14T10:53:04Z | |
| dc.date.accessioned | 2026-01-11T19:10:08Z | |
| dc.date.available | 2022-03-14T10:53:04Z | |
| dc.date.issued | 2020-07-16 | |
| dc.description.abstract | Multiple-unit systems may include tablets, capsules, pellets in a single administration. Once-a-day administration of Amlodipine Besylate (AML) accounts for fluctuation of plasma drug concentrations between dosing intervals. The aim of this study is to develop an extended-release (ER) and an immediate-release (IR) tablet to overcome the fluctuation of plasma drug concentrations. To achieve this purpose, 9 IR tablets and 6 ER tablet formulations were developed. The dissolution media for IR tablets was pH 2 for 1 hour and the dissolution media for ER tablets was pH 2 for 2 hours, and afterwards was pH 6.8 for 10 hours. The amount of AML released into the dissolution media was measured by Mettler Toledo UV 5 at a wavelength of 238 nm. The dissolution data of IR and ER tablets were statically evaluated. The highest dissolution rate for IR tablets (93%) was achieved with the IR-5 formulation. For ER tablets, a 50% drug release was achieved with the ER-1 and ER-4 formulation. The drug release kinetics of all ER tablets were calculated and subsequently the ER-1 formulation, which has Higuchi drug release kinetics, was chosen as the ER tablet. Lastly, a dissolution study of the selected formulations (IR-5 and ER-1) was conducted in the same vessel. After 12 hours of the dissolution study, drug release was found to be 79% +/- 0,92 (close to 75% which was targeted). Multiple-unit systems that have different tablet formulations in one administration could be used to enhance drug release kinetics that cannot be achieved with conventional tablets. | |
| dc.identifier.doi | 10.35333/jrp.2020.205 | |
| dc.identifier.issn | 2630-6344 | |
| dc.identifier.uri | https://hdl.handle.net/11424/245277 | |
| dc.identifier.wos | WOS:000551828000014 | |
| dc.language.iso | eng | |
| dc.publisher | MARMARA UNIV | |
| dc.relation.ispartof | JOURNAL OF RESEARCH IN PHARMACY | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Multiple unit system | |
| dc.subject | amlodipine besylate | |
| dc.subject | immediate release tablet | |
| dc.subject | extended release tablet | |
| dc.subject | fluctuation of plasma drug concentration | |
| dc.subject | hydroxyl propyl cellulose | |
| dc.subject | sodium starch glycolate | |
| dc.subject | crospovidon | |
| dc.subject | ORALLY DISINTEGRATING TABLETS | |
| dc.subject | DISSOLUTION ENHANCEMENT | |
| dc.subject | PHARMACOKINETICS | |
| dc.title | Development of a multiple-unit system: Tablets containing amlodipine besylate which have different release kinetics | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 581 | |
| oaire.citation.issue | 4 | |
| oaire.citation.startPage | 572 | |
| oaire.citation.title | JOURNAL OF RESEARCH IN PHARMACY | |
| oaire.citation.volume | 24 |
Files
Original bundle
1 - 1 of 1
